FG-4592: Phase IIa data

A single-blind, placebo-controlled, dose-escalation Phase IIa trial in 97 evaluable patients with stage 3/4 CKD showed that all patients treated with twice- (n=9) or thrice-weekly (n=11) 2 mg/kg oral ...